AdipoGenix is a biopharmaceutical company developing small molecule therapies for obesity, type 2 diabetes and associated morbidities, and Unigen is a leading natural products R&D facility and supplier
“Rinat is a pioneer in developing protein-based therapeutics and we see tremendous potential in its research to develop new medicines, notably for the treatment of Alzheimer’s disease,” said
The patch formulation of the active ingredient methylphenidate will be available in 10mg, 15mg, 20mg and 30mg dosage strengths. Daytrana is licensed globally to Shire by Noven Pharmaceuticals.
The primary objective of this phase II study is to determine the pathological response of A-007, a self-administered intravaginal gel, as compared to placebo in the treatment of
SB-509 represents a new approach in treating diabetic neuropathy, designed to directly protect and restore nerve function by up-regulating the expression of the gene encoding vascular endothelial growth
The decision to withdraw the application was made based on the company’s ongoing discussions with the US Food & Drug Administration regarding the Lo Seasonale NDA and the
Subject to FDA acceptance and Institutional Review Board approval at the planned clinical site, Cytogen will begin its first phase I clinical trial of CYT-500 in patients with
The nine-month phase II study of 90 patients with relapsing-remitting multiple sclerosis (RRMS) compared a 40 mg dose of Copaxone to the currently approved 20 mg dose. Brain
Supprelin LA was evaluated as a 12-month implant for treating central precocious puberty (CPP), or the early onset of puberty. The multi-center, open-label study involved 36 patients, primarily
Hexvix, which is developed for the detection of bladder cancer, is based on photodynamic technology that combines a photosensitiser drug with a light source that activates the photosensitiser.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.